WO2000076480A3 - Pharmaceutical materials and methods for their preparation and use - Google Patents

Pharmaceutical materials and methods for their preparation and use Download PDF

Info

Publication number
WO2000076480A3
WO2000076480A3 PCT/US2000/016140 US0016140W WO0076480A3 WO 2000076480 A3 WO2000076480 A3 WO 2000076480A3 US 0016140 W US0016140 W US 0016140W WO 0076480 A3 WO0076480 A3 WO 0076480A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystals
methods
active pharmaceutical
administering
crystal lattice
Prior art date
Application number
PCT/US2000/016140
Other languages
French (fr)
Other versions
WO2000076480A2 (en
WO2000076480A9 (en
Inventor
Jean A Chmielewski
Bart E Kahr
Jerry Lewis
Original Assignee
Lilly Co Eli
Jean A Chmielewski
Bart E Kahr
Jerry Lewis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Jean A Chmielewski, Bart E Kahr, Jerry Lewis filed Critical Lilly Co Eli
Priority to EP00939811A priority Critical patent/EP1189599A2/en
Priority to US10/018,043 priority patent/US7001892B1/en
Priority to AU54836/00A priority patent/AU5483600A/en
Publication of WO2000076480A2 publication Critical patent/WO2000076480A2/en
Publication of WO2000076480A3 publication Critical patent/WO2000076480A3/en
Publication of WO2000076480A9 publication Critical patent/WO2000076480A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions comprising crystals of a pharmaceutically-acceptable crystal lattice component, and an active pharmaceutical ingredient different from and included within the crystal lattice component in a growth-sector specific orientation. The crystals are prepared using components and methods which yield crystals having suitable purity and efficacy for use in administering the active pharmaceutical ingredients to a patient. The crystals are typically combined with adjuvants such as excipients, diluents or carriers, and are preferably formulated into tablets, capsules, suspensions, and other conventional forms containing predetermined amounts of the pharmaceuticals. Also provided are methods for preparing the crystals, and methods for storing and administering the active pharmaceutical ingredient either included within the crystals or upon reconstitution of the crystals to a solution.
PCT/US2000/016140 1999-06-11 2000-06-12 Pharmaceutical materials and methods for their preparation and use WO2000076480A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00939811A EP1189599A2 (en) 1999-06-11 2000-06-12 Pharmaceutical materials and methods for their preparation and use
US10/018,043 US7001892B1 (en) 1999-06-11 2000-06-12 Pharmaceutical materials and methods for their preparation and use
AU54836/00A AU5483600A (en) 1999-06-11 2000-06-12 Pharmaceutical materials and methods for their preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13891299P 1999-06-11 1999-06-11
US60/138,912 1999-06-11

Publications (3)

Publication Number Publication Date
WO2000076480A2 WO2000076480A2 (en) 2000-12-21
WO2000076480A3 true WO2000076480A3 (en) 2001-04-19
WO2000076480A9 WO2000076480A9 (en) 2002-07-11

Family

ID=22484233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016140 WO2000076480A2 (en) 1999-06-11 2000-06-12 Pharmaceutical materials and methods for their preparation and use

Country Status (3)

Country Link
EP (1) EP1189599A2 (en)
AU (1) AU5483600A (en)
WO (1) WO2000076480A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
EP1986612B1 (en) 2006-02-07 2012-09-12 Shire Human Genetic Therapies, Inc. Stabilized composition of glucocerebrosidase
WO2011017177A1 (en) * 2009-07-28 2011-02-10 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
KR102096752B1 (en) 2012-03-02 2020-04-02 샤이어 휴먼 지네틱 테라피즈 인크. Compositions and methods for treating type iii gaucher disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0119480A2 (en) * 1983-02-23 1984-09-26 BASF Aktiengesellschaft Spherical monocrystals for pharmaceutical use
GB2160100A (en) * 1984-06-14 1985-12-18 Sandoz Ltd Galenical retard formulations
EP0314469A2 (en) * 1987-10-27 1989-05-03 Fujitsu Limited Process and apparatus for preparation of single crystal of biopolymer
EP0435450A2 (en) * 1989-11-22 1991-07-03 SPI POLYOLS, Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
EP0629393A2 (en) * 1993-06-16 1994-12-21 ICI AMERICAS Inc. A crystalline polyol composition
WO1997021838A1 (en) * 1995-12-11 1997-06-19 Eridania Beghin-Say Microcrystalline sugars or sugar-alcohols; method for preparing the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0119480A2 (en) * 1983-02-23 1984-09-26 BASF Aktiengesellschaft Spherical monocrystals for pharmaceutical use
GB2160100A (en) * 1984-06-14 1985-12-18 Sandoz Ltd Galenical retard formulations
EP0314469A2 (en) * 1987-10-27 1989-05-03 Fujitsu Limited Process and apparatus for preparation of single crystal of biopolymer
EP0435450A2 (en) * 1989-11-22 1991-07-03 SPI POLYOLS, Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
EP0629393A2 (en) * 1993-06-16 1994-12-21 ICI AMERICAS Inc. A crystalline polyol composition
WO1997021838A1 (en) * 1995-12-11 1997-06-19 Eridania Beghin-Say Microcrystalline sugars or sugar-alcohols; method for preparing the same

Also Published As

Publication number Publication date
WO2000076480A2 (en) 2000-12-21
AU5483600A (en) 2001-01-02
WO2000076480A9 (en) 2002-07-11
EP1189599A2 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
WO2005065185A3 (en) Temperature-stable formulations, and methods of development thereof
ES2324527T3 (en) STABILIZED AZITHROMYCIN COMPOSITIONS.
CA2192418C (en) New crystal modification of cdch, a process for its preparation and pharmaceutical formulations comprising this modification
EP2688575B1 (en) Lithium compositions
OA12806A (en) Novel perindopril salt and pharmaceutical compositions containing same.
CA2049302A1 (en) Aerosol carriers
KR20010101128A (en) Stabilization of Macrolides
CA2221341A1 (en) Submicron liposome suspensions obtained from preliposome lyophilizates
JP2018035162A (en) Methods for treatment of diseases
ES2910003T3 (en) Organic Anion Lithium Ionic Cocrystal Compounds and Compositions
NO883229D0 (en) NEW BENZIMIDAZOLD DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATION CONTAINING SUCH DERIVATIVES.
WO2000076480A3 (en) Pharmaceutical materials and methods for their preparation and use
KR20190115000A (en) Tevipenem cladding crystalline form, compositions comprising the same, methods of preparation, and methods of use
WO2002000166A3 (en) New compounds useful as antibacterial agents
AU2003273473A1 (en) Novel substituted pyrazolo(1,5 less thanigreater thanaless than/igreater than)-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
HK65193A (en) Nicorandil-containing preparation for injection
JP2008509914A5 (en)
JP2004517808A5 (en)
US4772589A (en) Etoposide solution in NMP
HRP20000291B1 (en) High purity (1r, 2s, 4r)-(-)-2-/(2'-/n,n-dimethylamino/-ethoxy)/-2-/phenyl/-1,7,7-tri-/methyl/bicyclo/2.2.1/ heptane and pharmaceutically acceptable acid addition salts thereof and process for the preparation of these compounds as well medicaments containing one or more of them and the use thereof
EP0190851B1 (en) Improved antiinflammatory composition
WO2000066550A8 (en) New compounds
UY26459A1 (en) 3,4-DIHIDROQUINAZOLINES 5,6-DISSTITUTED
CA2493208A1 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000939811

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000939811

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10018043

Country of ref document: US

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 18-57, DESCRIPTION, REPLACED BY NEW PAGES 18-57; PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000939811

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP